The integration of metabolic data with RECIST 1.1 criteria increased clinical confidence in maintaining immunotherapy despite transient risks of pseudoprogression, a phenomenon increasingly recognized in PD-L1 inhibitor-treated sarcomas (18, 19). This evidence concerns the gene CD274 and sarcoma.